cause for concern is that the testing of the C auris isolates demonstrated that nearly all exhibited varying levels of resistance to multiple classes of antifungal drugs—including azoles, echinocandins, and polyenes. That finding indicates that treatment options for C auris infections could be limited.A fungus that is resistant to the three major classes of antifungal drugs “could be a real management challenge,” Chiller noted.The other challenge is that C auris is difficult to identify. The CDC said biochemical-based tests cannot differentiate between C auris and other invasive Candida infections, so the pathogen can be misidentified and potentially treated inappropriately. Originally, Chiller said, many of the infections were identified as C haemulonii before being correctly identified as C auris. Chiller said hospitals need molecular techniques to correctly identify C auris infections.Chiller also noted that the fungal infection is emerging simultaneously on different continents. While the isolates appear to be highly related within the countries reporting infections, they are highly distinct between continents.
Source: CDC issues warning on multidrug-resistant yeast infection | CIDRAP










You must be logged in to post a comment.